皮下注射利妥昔单抗对比静脉注射利妥昔单抗一线治疗滤泡性淋巴瘤的疗效与安全性(SABRINA):一项随机、开放标签、3期试验
SABRINA是一项在30个国家113个中心开展的两阶段随机开放标签3期研究,410例初治CD20阳性1-3a级滤泡性淋巴瘤患者按1:1随机接受静脉利妥昔单抗375 mg/m²或皮下利妥昔单抗1400 mg,联合CHOP或CVP化疗。诱导结束时静脉组研究者评估总缓解率为84.9%,皮下组为84.4%,两组不良事件频率相似,皮下组给药相关反应更常见(主要为1-2级局部注射部位反应)。结论认为两种给药方式疗效和安全性相似,皮下给药不损害利妥昔单抗的抗淋巴瘤活性。
要点
- 诱导结束时总缓解率静脉组84.9%(95%CI 79.2-89.5),皮下组84.4%(95%CI 78.7-89.1)。
- ≥3级不良事件静脉组55%(116/210) vs 皮下组56%(111/197),最常见为中性粒细胞减少。
- 给药相关反应静脉组35%(73例) vs 皮下组48%(95例),主要为1-2级局部注射部位反应。
核心结论
- 静脉与皮下利妥昔单抗疗效和安全性相似,未发现新的安全性问题。
- 与化疗联合时,皮下给药不损害利妥昔单抗的抗淋巴瘤活性。
研究设计与样本
- SABRINA为两阶段、随机、开放标签3期研究,在30个国家113个中心开展。
- 纳入410例初治CD20阳性1、2或3a级滤泡性淋巴瘤患者,按1:1随机分至静脉利妥昔单抗375 mg/m²组(205例)或皮下利妥昔单抗1400 mg组(205例)。
- 两组均联合6-8周期CHOP或8周期CVP化疗,每3周一次诱导,随后每8周利妥昔单抗维持治疗。
- 随机按所选化疗方案、滤泡性淋巴瘤国际预后指数和地区分层。
- 主要终点为第二阶段诱导结束时的总缓解(确证完全缓解、未确证完全缓解和部分缓解),在意向治疗人群中分析。
主要发现
- 诱导结束时研究者评估总缓解率:静脉组84.9%(95%CI 79.2-89.5) vs 皮下组84.4%(95%CI 78.7-89.1)。
- 不良事件频率:静脉组199/210(95%) vs 皮下组189/197(96%)。
- ≥3级不良事件频率:静脉组116/210(55%) vs 皮下组111/197(56%)。
- 最常见的≥3级不良事件为中性粒细胞减少:静脉组44例(21%) vs 皮下组52例(26%)。
- 严重不良事件:静脉组72例(34%) vs 皮下组73例(37%);给药相关反应:静脉组73例(35%) vs 皮下组95例(48%),主要为1-2级局部注射部位反应。
关键数值与推荐
- 静脉利妥昔单抗剂量为375 mg/m²,皮下利妥昔单抗剂量为1400 mg。
- 诱导期化疗为6-8周期CHOP或8周期CVP,每3周一次;维持期利妥昔单抗每8周一次。
临床怎么用
- 原文结论认为静脉与皮下利妥昔单抗疗效和安全性相似,皮下给药不损害抗淋巴瘤活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety data. METHODS: SABRINA is a two-stage, randomised, open-label phase 3 study at 113 centres in 30 countries. Eligible patients were aged 18 years or older and had histologically confirmed, previously untreated, CD20-positive grade 1, 2, or 3a follicular lymphoma; Eastern Co-operative Oncology Group performance statuses of 0-2; bidimensionally measurable disease (by CT or MRI); life expectancy of 6 months or more; adequate haematological function for 28 days or more; and one or more symptoms requiring treatment according to the Groupe d'Etudes des Lymphomes Folliculaires criteria. Patients were randomly assigned (1:1) by investigators or members of the research team via a dynamic randomisation algorithm to 375 mg/m2 intravenous rituximab or 1400 mg subcutaneous rituximab, plus chemotherapy (six-to-eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or eight cycles of cyclophosphamide, vincristine, and prednisone [CVP]), every 3 weeks during induction, then rituximab maintenance every 8 weeks. Randomisation was stratified by selected chemotherapy, Follicular Lymphoma International Prognostic Index, and region. The primary endpoint for stage 2 was overall response (ie, confirmed complete response, unconfirmed complete response, and partial response) at the end of induction. Efficacy analyses were done in the intention-to-treat population. Pooled data from stages 1 and 2 are reported on the basis of the clinical cutoff date of the last patient completing the maintenance phase of the study. This trial is registered with ClinicalTrials.gov, number NCT01200758; new patients are no longer being recruited, but some patients are still being followed up. FINDINGS: Between Feb 15, 2011, and May 15, 2013, 410 patients were randomly assigned, 205 to intravenous rituximab and 205 to subcutaneous rituximab. Investigator-assessed overall response at the end of induction was 84·9% (95% CI 79·2-89·5) in the intravenous group and 84·4% (78·7-89·1) in the subcutaneous group. The frequency of adverse events was similar in both groups (199 [95%] of 210 in the intravenous group vs 189 [96%] of 197 in the subcutaneous group); the frequency of adverse events of grade 3 or higher was also similar (116 [55%] vs 111 [56%]). The most common grade 3 or higher adverse event was neutropenia, which occurred in 44 patients (21%) in the intravenous group and 52 (26%) in the subcutaneous group. Serious adverse events occurred in 72 patients (34%) in the intravenous group and 73 (37%) in the subcutaneous group. Administration-related reactions occurred in 73 patients (35%) in the intravenous group and 95 (48%) patients in the subcutaneous group (mainly grade 1 or 2 local injection-site reactions). INTERPRETATION: Intravenous and subcutaneous rituximab had similar efficacy and safety profiles, and no new safety concerns were noted. Subcutaneous administration does not compromise the anti-lymphoma activity of rituximab when given with chemotherapy. FUNDING: F Hoffmann-La Roche.
引用
- Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017. PMID: 28476440. doi:10.1016/S2352-3026(17)30078-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。